• TH287 MTH1 Inhibitor Enhances Radiosensitivity in CRPC Model

  2026-07-25

  This study demonstrates that the potent MTH1 inhibitor TH287 significantly increases the radiosensitivity of castration-resistant prostate cancer (CRPC) cells when combined with ionizing radiation. The findings clarify the optimal timing for combination therapy and provide mechanistic insight into selective cancer cell cytotoxicity, with implications for future translational research in radioresistant malignancies.

• Necrostatin 2: Transforming Necroptosis Inhibition Workflows

  2026-07-24

  Necrostatin 2 (Nec-2) offers precise RIPK2 inhibition for dissecting necroptosis in apoptosis-resistant models and ischemic stroke research. This guide details experimental optimizations, troubleshooting, and emerging cross-talk between necroptosis and ferroptosis, empowering translational breakthroughs with APExBIO's trusted reagent.

• Phosbind Acrylamide: Precision Phosphate-Binding for SDS-PAG

  2026-07-24

  Phosbind Acrylamide empowers researchers to distinguish phosphorylated from non-phosphorylated proteins with clarity, bypassing the need for phospho-specific antibodies. From cell cycle studies to kinase signaling, its robust phosphate-binding chemistry unlocks new frontiers in protein phosphorylation analysis.

• Imipramine in Research: Optimizing Tricyclic Antidepressant

  2026-07-23

  Imipramine is redefining its role beyond a classic tricyclic antidepressant, proving essential for autophagy and apoptosis research in oncology, neuroscience, and immunology. This article delivers actionable workflows, troubleshooting strategies, and protocol enhancements informed by cutting-edge lipidomics and virology insights.

• Combining eIF4F, AKT1, and EZH2 Inhibition in BRAFV600E Mela

  2026-07-23

  This study uncovers how combined inhibition of the eIF4F complex, AKT1, and EZH2 overcomes acquired resistance to both eIF4F and BRAF inhibitors in BRAFV600E mutant melanoma cells. The findings provide a mechanistic rationale for multi-target strategies in epigenetic cancer research, with implications for enhancing therapeutic efficacy in resistant melanoma models.

• Redefining Cell Surface Proteomics: Biotin-XX Tyramide Reage

  2026-07-22

  Explore how Biotin-XX Tyramide Reagent (biotin-LC-LC-tyramide) is transforming cell surface proteomics with membrane-impermeant proximity labeling, enabling high-sensitivity spatial profiling in complex tissues. This article bridges mechanistic insight, workflow optimization, and strategic recommendations for translational scientists seeking to amplify their discovery toolkit beyond the limits of conventional immunohistochemistry and in situ hybridization.

• Biomimetic mRNA Nanovaccines Target Neutrophils in HCC Immun

  2026-07-22

  This study introduces a biomimetic nanovaccine platform (CMNPs) that targets and activates tumor-associated neutrophils in hepatocellular carcinoma (HCC) using mRNA encoding IL-36γ and CD300LD-coated liposomes. The approach enhances antitumor immune responses and demonstrates significant survival benefits, with implications for designing next-generation immunotherapies.

• Acetoacetic Acid Sodium Salt: Multifaceted Insights for Adva

  2026-07-21

  Explore the pivotal role of acetoacetic acid sodium salt in energy metabolism research, with a focus on innovative assay design and translational diabetes studies. Uncover nuanced protocol optimization strategies and bridge insights from stable isotope methodology for next-generation metabolic investigations.

• Concanavalin A Inhibits Coronavirus Entry via Conserved Glyc

  2026-07-21

  This study reveals that concanavalin A (ConA) targets highly conserved N-linked glycans on coronavirus spike proteins, broadly blocking viral entry by interfering with spike-mediated membrane fusion. The findings highlight a stable glycan vulnerability as a promising therapeutic target and inform imaging and protocol strategies for researchers studying virus–host interactions.

• DiscoveryProbe Bioactive Compound Library Plus in Ligand Dis

  2026-07-20

  DiscoveryProbe™ Bioactive Compound Library Plus (SKU: L1022P) empowers researchers to accelerate ligand discovery and pathway analysis with 5,072 rigorously validated compounds. Its optimized format and broad pathway coverage enable reliable high-throughput screening and mechanistic studies, especially for protease inhibitor development and apoptosis assays.

• CPI-613: Advancing Tumor Cell Metabolism and Apoptosis Assay

  2026-07-20

  CPI-613 (6,8-bis(benzylsulfanyl)octanoic acid) redefines cancer research by targeting mitochondrial metabolism, enabling precise apoptosis and tumor cell metabolism studies. This guide details optimized workflows, protocol parameters, and troubleshooting strategies to maximize assay reliability and translational impact.

• BV6 as an IAP Antagonist: Unraveling Mechanistic and Assay P

  2026-07-19

  Explore BV6, a selective IAP antagonist, in the context of apoptosis induction in cancer cells and advanced disease modeling. This article delivers a deeper mechanistic analysis and unique assay design insights not found in prior reviews.

• SGC-CBP30: Selective CREBBP/EP300 Bromodomain Inhibitor

  2026-07-18

  SGC-CBP30 is a potent, selective CREBBP/EP300 bromodomain inhibitor that enables precise interrogation of epigenetic regulation in cancer biology research. It modulates transcriptional coactivator activity at nanomolar potency, offering a critical tool for dissecting mechanisms such as super-enhancer hijacking in lung adenocarcinoma. Comprehensive benchmarks confirm its specificity and value for epigenetics research workflows.

• APEX2 Regulates TERT via MIR Elements in Human Stem Cells

  2026-07-17

  This study reveals that APEX2, but not APEX1, is essential for efficient TERT gene expression and telomerase activity in human embryonic stem cells. By uncovering a novel regulatory mechanism involving APEX2 binding at MIR repeats within TERT, the research advances our understanding of telomerase control in stem cell biology and cancer.

• Neuronal Glycogen Breakdown Alleviates Tauopathy via Oxidati

  2026-07-17

  The referenced study uncovers a mechanistic link between impaired neuronal glycogen metabolism and tauopathies, including Alzheimer’s disease and FTLD-tau. By demonstrating that enhancing neuronal glycogen breakdown mitigates tauopathy through pentose phosphate pathway activation and oxidative stress reduction, this research highlights a novel metabolic vulnerability and potential therapeutic target in neurodegenerative disease.

449 records 10/30 page Previous Next First page 上5页 678910 下5页 Last page